CN102068474A - 刺山柑果凝胶膏剂及其生产方法和抗风湿药物的应用 - Google Patents
刺山柑果凝胶膏剂及其生产方法和抗风湿药物的应用 Download PDFInfo
- Publication number
- CN102068474A CN102068474A CN2010106121586A CN201010612158A CN102068474A CN 102068474 A CN102068474 A CN 102068474A CN 2010106121586 A CN2010106121586 A CN 2010106121586A CN 201010612158 A CN201010612158 A CN 201010612158A CN 102068474 A CN102068474 A CN 102068474A
- Authority
- CN
- China
- Prior art keywords
- spinosae radicis
- cortex capparis
- capparis spinosae
- fruit
- cortex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 153
- 239000002674 ointment Substances 0.000 title claims abstract description 75
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 12
- 230000003356 anti-rheumatic effect Effects 0.000 title abstract description 4
- 239000003435 antirheumatic agent Substances 0.000 title abstract description 4
- 244000140995 Capparis spinosa Species 0.000 title abstract 4
- 235000017336 Capparis spinosa Nutrition 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 21
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims abstract description 8
- 239000004698 Polyethylene Substances 0.000 claims abstract description 6
- 239000004744 fabric Substances 0.000 claims abstract description 6
- 229920000573 polyethylene Polymers 0.000 claims abstract description 6
- 229920000742 Cotton Polymers 0.000 claims abstract description 4
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000002131 composite material Substances 0.000 claims abstract description 4
- 229920000728 polyester Polymers 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 241000722721 Capparis Species 0.000 claims description 175
- 239000000499 gel Substances 0.000 claims description 78
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- 230000008961 swelling Effects 0.000 claims description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000012530 fluid Substances 0.000 claims description 20
- 238000010438 heat treatment Methods 0.000 claims description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 15
- 208000002193 Pain Diseases 0.000 claims description 15
- 230000036407 pain Effects 0.000 claims description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 15
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 15
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 12
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000003431 cross linking reagent Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000002562 thickening agent Substances 0.000 claims description 11
- 239000000080 wetting agent Substances 0.000 claims description 11
- 238000004132 cross linking Methods 0.000 claims description 10
- 239000013530 defoamer Substances 0.000 claims description 10
- 239000000945 filler Substances 0.000 claims description 10
- 239000003961 penetration enhancing agent Substances 0.000 claims description 10
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 9
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 9
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 7
- 239000011975 tartaric acid Substances 0.000 claims description 7
- 235000002906 tartaric acid Nutrition 0.000 claims description 7
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 201000005569 Gout Diseases 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 239000004408 titanium dioxide Substances 0.000 claims description 6
- 239000005995 Aluminium silicate Substances 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 206010034464 Periarthritis Diseases 0.000 claims description 5
- 235000012211 aluminium silicate Nutrition 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000003643 water by type Substances 0.000 claims description 4
- KILURZWTCGSYRE-LNTINUHCSA-K (z)-4-bis[[(z)-4-oxopent-2-en-2-yl]oxy]alumanyloxypent-3-en-2-one Chemical compound CC(=O)\C=C(\C)O[Al](O\C(C)=C/C(C)=O)O\C(C)=C/C(C)=O KILURZWTCGSYRE-LNTINUHCSA-K 0.000 claims description 3
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000004411 aluminium Substances 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 3
- 239000000347 magnesium hydroxide Substances 0.000 claims description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 229920000570 polyether Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- RBNPZEHAODHBPZ-UHFFFAOYSA-M dihydroxyaluminium Chemical compound O.O.NCC(=O)O[Al] RBNPZEHAODHBPZ-UHFFFAOYSA-M 0.000 claims 1
- 230000009471 action Effects 0.000 abstract description 5
- 241000196324 Embryophyta Species 0.000 abstract description 4
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 3
- 230000035699 permeability Effects 0.000 abstract description 3
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 238000010579 first pass effect Methods 0.000 abstract description 2
- 230000009610 hypersensitivity Effects 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract 2
- 206010022998 Irritability Diseases 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 239000002985 plastic film Substances 0.000 abstract 1
- 229920006255 plastic film Polymers 0.000 abstract 1
- 238000002481 ethanol extraction Methods 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 26
- 229940079593 drug Drugs 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- 206010070834 Sensitisation Diseases 0.000 description 18
- 230000008313 sensitization Effects 0.000 description 18
- 241000700199 Cavia porcellus Species 0.000 description 16
- 206010015150 Erythema Diseases 0.000 description 15
- 239000006071 cream Substances 0.000 description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 11
- 210000002683 foot Anatomy 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 231100000321 erythema Toxicity 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 206010002198 Anaphylactic reaction Diseases 0.000 description 9
- 208000003455 anaphylaxis Diseases 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 230000036783 anaphylactic response Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 8
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 241000195622 Astasia Species 0.000 description 5
- 206010010947 Coordination abnormal Diseases 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000013521 mastic Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical group [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 229920006267 polyester film Polymers 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 239000004567 concrete Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000035617 depilation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010051814 Eschar Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 229940085332 aspirin 800 mg Drugs 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 231100000333 eschar Toxicity 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000873224 Capparaceae Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 244000100068 Triphasia aurantiola Species 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 动物数(只) | 剂量g/kg | 肿胀度mg | 抑制率% |
对照组(DW) | 10 | - | 18.60±4.67 | - |
刺山柑果水提取物小剂量 | 10 | 1.7 | 19.00±2.67 | -2.15 |
刺山柑果水提取物大剂量 | 10 | 3.4 | 17.40±7.20 | 6.45 |
刺山柑果50%乙醇提取物小剂量 | 10 | 1.7 | 18.30±5.23 | 1.61 |
刺山柑果50%乙醇提取物大剂量 | 10 | 3.4 | 17.50±6.43 | 5.91 |
刺山柑果90%乙醇提取物小剂量 | 10 | 1.5 | 17.30±5.62 | 6.99 |
刺山柑果90%乙醇提取物大剂量 | 10 | 3.0 | 16.70±4.03 | 10.22 |
刺山柑果90%+50%乙醇提取物小剂量 | 10 | 1.5 | 17.90±5.57 | 3.76 |
刺山柑果90%+50%乙醇提取物大剂量 | 10 | 3.0 | 16.10±4.20 | 13.44 |
刺山柑果细粉小剂量 | 10 | 0.9 | 16.90±5.84 | 9.14 |
刺山柑果细粉大剂量 | 10 | 1.8 | 13.10±3.48** | 29.57 |
刺山柑果95%乙醇提取物小剂量 | 10 | 3.0 | 16.88±6.26 | 9.02 |
刺山柑果95%乙醇提取物大剂量 | 10 | 1.5 | 13.12±2.32** | 28.55 |
组别 | 动物数(只) | 剂量g/kg | 扭体次数(次) | 抑制率% |
对照组(DW) | 10 | - | 39.10±12.84 | - |
刺山柑果水提取物小剂量 | 10 | 1.7 | 39.30±17.51 | -0.51 |
刺山柑果水提取物大剂量 | 10 | 3.4 | 35.20±16.48 | 9.97 |
刺山柑果50%乙醇提取物小剂量 | 10 | 1.7 | 35.00±14.63 | 10.49 |
刺山柑果50%乙醇提取物大剂量 | 10 | 3.4 | 41.40±15.20 | -5.88 |
刺山柑果90%乙醇提取物小剂量 | 10 | 1.5 | 36.60±11.68 | 6.39 |
刺山柑果90%乙醇提取物大剂量 | 10 | 3.0 | 29.30±17.54 | 25.06 |
刺山柑果90%+50%乙醇提取物小剂量 | 10 | 1.5 | 37.00±10.74 | 5.37 |
刺山柑果90%+50%乙醇提取物大剂量 | 10 | 3.0 | 28.70±8.23* | 26.60 |
刺山柑果细粉小剂量 | 10 | 0.9 | 32.60±9.67 | 16.62 |
刺山柑果细粉大剂量 | 10 | 1.8 | 28.00±6.58* | 28.39 |
刺山柑果95%乙醇提取物小剂量 | 10 | 3.0 | 32.40±9.67 | 15.44 |
刺山柑果95%乙醇提取物大剂量 | 10 | 1.5 | 27.10±5.66* | 27.25 |
刺激反应情况 | 分值 |
(1) 红斑: | |
无红斑 | 0 |
轻度红斑,勉强可见 | 1 |
中度红斑,明显可见 | 2 |
重度红斑 | 3 |
紫红色红斑并有焦痂形成 | 4 |
(2)水肿: | |
无水肿 | 0 |
轻度水肿,勉强可见 | 1 |
中度水肿,明显可见(边缘高出皮肤周围) | 2 |
重度水肿,皮肤隆起约1mm,轮廓清楚 | 3 |
严重水肿,水肿隆起1mm以上或有水泡或破溃 | 4 |
最后总分值 | 8 |
过敏发生率(%) | 皮肤致敏性评价 |
0—10 | 无致敏性 |
11—30 | 轻度致敏性 |
31—60 | 中度致敏性 |
61—80 | 高度致敏性 |
81—100 | 极度致敏性 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010106121586A CN102068474B (zh) | 2010-12-29 | 2010-12-29 | 刺山柑果凝胶膏剂及其生产方法和抗风湿药物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010106121586A CN102068474B (zh) | 2010-12-29 | 2010-12-29 | 刺山柑果凝胶膏剂及其生产方法和抗风湿药物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102068474A true CN102068474A (zh) | 2011-05-25 |
CN102068474B CN102068474B (zh) | 2012-11-14 |
Family
ID=44027353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010106121586A Active CN102068474B (zh) | 2010-12-29 | 2010-12-29 | 刺山柑果凝胶膏剂及其生产方法和抗风湿药物的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102068474B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102309539A (zh) * | 2011-09-22 | 2012-01-11 | 广东药学院 | 一种皂角刺提取物水凝胶帖及其制备方法 |
CN102641371A (zh) * | 2012-05-08 | 2012-08-22 | 辽宁中医药大学附属医院 | 一种治疗体表感染性疾病的巴布剂 |
WO2016141758A1 (zh) * | 2015-03-12 | 2016-09-15 | 施敬东 | 醒脑清凉贴及其制备方法 |
CN105963678A (zh) * | 2016-05-17 | 2016-09-28 | 莆田学院附属医院 | 一种环孢素a微乳巴布膏眼贴及其制备方法 |
CN108617653A (zh) * | 2018-05-07 | 2018-10-09 | 柯江波 | 基于滩涂淤泥的扦插繁殖用缓释抑菌剂及制备方法 |
CN111568885A (zh) * | 2020-06-14 | 2020-08-25 | 陕西健吉跃生物科技有限公司 | 一种含烟酰胺的水凝胶贴剂及其制备方法和应用 |
CN113209008A (zh) * | 2021-05-27 | 2021-08-06 | 新疆维吾尔自治区药物研究所 | 睡莲多酚凝胶剂及其制备方法和应用 |
CN114259438A (zh) * | 2021-12-21 | 2022-04-01 | 上海珈凯生物科技有限公司 | 一种刺山柑果复合液及其制备方法和应用 |
CN114366762A (zh) * | 2022-02-28 | 2022-04-19 | 新奇康药业股份有限公司 | 一种刺山柑果膏及其制备方法 |
-
2010
- 2010-12-29 CN CN2010106121586A patent/CN102068474B/zh active Active
Non-Patent Citations (1)
Title |
---|
《安徽中医学院学报》 20060430 柯仲成等 中药巴布剂的研究进展 56-58 1-4 第25卷, 第2期 2 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102309539A (zh) * | 2011-09-22 | 2012-01-11 | 广东药学院 | 一种皂角刺提取物水凝胶帖及其制备方法 |
CN102309539B (zh) * | 2011-09-22 | 2013-06-12 | 广东药学院 | 一种皂角刺提取物水凝胶贴及其制备方法 |
CN102641371A (zh) * | 2012-05-08 | 2012-08-22 | 辽宁中医药大学附属医院 | 一种治疗体表感染性疾病的巴布剂 |
WO2016141758A1 (zh) * | 2015-03-12 | 2016-09-15 | 施敬东 | 醒脑清凉贴及其制备方法 |
CN105963678A (zh) * | 2016-05-17 | 2016-09-28 | 莆田学院附属医院 | 一种环孢素a微乳巴布膏眼贴及其制备方法 |
CN108617653A (zh) * | 2018-05-07 | 2018-10-09 | 柯江波 | 基于滩涂淤泥的扦插繁殖用缓释抑菌剂及制备方法 |
CN111568885A (zh) * | 2020-06-14 | 2020-08-25 | 陕西健吉跃生物科技有限公司 | 一种含烟酰胺的水凝胶贴剂及其制备方法和应用 |
CN113209008A (zh) * | 2021-05-27 | 2021-08-06 | 新疆维吾尔自治区药物研究所 | 睡莲多酚凝胶剂及其制备方法和应用 |
CN114259438A (zh) * | 2021-12-21 | 2022-04-01 | 上海珈凯生物科技有限公司 | 一种刺山柑果复合液及其制备方法和应用 |
CN114259438B (zh) * | 2021-12-21 | 2023-11-14 | 上海珈凯生物股份有限公司 | 一种刺山柑果复合液及其制备方法和应用 |
CN114366762A (zh) * | 2022-02-28 | 2022-04-19 | 新奇康药业股份有限公司 | 一种刺山柑果膏及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102068474B (zh) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102068474B (zh) | 刺山柑果凝胶膏剂及其生产方法和抗风湿药物的应用 | |
CN100569273C (zh) | 一种用于治疗皮肤瘤、癣、疣、疱疹的外用中药 | |
CN103961636B (zh) | 一种治疗骨科疾病的外用中药组合物及制备方法和应用 | |
CN102406840B (zh) | 一种肿痛凝胶膏剂及其制备方法 | |
CN102058673B (zh) | 一种祛风除湿的中药组合物及其制备方法 | |
CN102380015B (zh) | 治疗类风湿性关节炎的药物组合物及其制备方法和用途 | |
CN104208288A (zh) | 一种抗炎镇痛外用制剂及其制备方法与用途 | |
CN102920915A (zh) | 治疗痔疮的软膏制剂及制备方法 | |
CN1084765A (zh) | 消瘀接骨灵 | |
CN102579583A (zh) | 治疗筋伤的外用贴剂 | |
CN104274546A (zh) | 一种外用中药组合物、外用中药制剂及其制备方法和应用 | |
CN101926815B (zh) | 一种治疗类风湿关节炎和湿疹的芍药苷和甘草次酸组合物及其制备方法与应用 | |
CN101732668A (zh) | 一种治疗泌尿系统感染的中药组合物的制备方法 | |
CN106176784A (zh) | 一种用于皮炎的药物组合物、应用、制剂及其制备方法 | |
CN101244187B (zh) | 治疗妇科疾病的栓剂 | |
CN100560103C (zh) | 血府逐瘀膏剂 | |
CN103432217B (zh) | 一种治疗类风湿性关节炎的外用药物组合物及其制备方法和用途 | |
CN101744873A (zh) | 一种含有独一味环烯醚萜苷的外用液体制剂及其应用 | |
CN101703667B (zh) | 一种竭红跌打药剂及其制备方法 | |
CN108078868A (zh) | 一种用于护肤品的抗过敏组合物 | |
CN102526387B (zh) | 一种治疗早期糖尿病足的药物组合物及制备方法 | |
CN103768454B (zh) | 一种具有预防和治疗hiv/aids的组合物及其制备方法 | |
CN106236791A (zh) | 骆驼蓬总碱乳膏剂及其制备方法 | |
CN1297251C (zh) | 辣椒风湿凝胶 | |
CN111298075A (zh) | 一种中药组合物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240122 Address after: Room 1701-167, Tianhe Plaza, No. 320 Tianjin North Road, High tech Zone (New City District), Urumqi, Xinjiang Uygur Autonomous Region, 830011 Patentee after: Xinjiang elexin Biotechnology Co.,Ltd. Country or region after: China Address before: 830004 No. 140 Xinhua South Road, the Xinjiang Uygur Autonomous Region, Urumqi Patentee before: XINJIANG INSTITUTE OF MATERIA MEDICA Country or region before: China |
|
TR01 | Transfer of patent right |